Company Quick10K Filing
Johnson & Johnson
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 2,697 $379,441
10-K 2020-02-18 Annual: 2019-12-29
10-Q 2019-10-28 Quarter: 2019-09-29
10-Q 2019-07-29 Quarter: 2019-06-30
10-Q 2019-05-01 Quarter: 2019-03-31
10-K 2019-02-20 Annual: 2018-12-30
10-Q 2018-10-31 Quarter: 2018-09-30
10-Q 2018-08-02 Quarter: 2018-07-01
10-Q 2018-05-01 Quarter: 2018-04-01
10-K 2018-02-21 Annual: 2017-12-31
10-Q 2017-11-02 Quarter: 2017-10-01
10-Q 2017-08-03 Quarter: 2017-07-02
10-Q 2017-05-08 Quarter: 2017-04-02
10-K 2017-02-27 Annual: 2017-01-01
10-Q 2016-11-04 Quarter: 2016-10-02
10-Q 2016-08-04 Quarter: 2016-07-03
10-Q 2016-05-10 Quarter: 2016-04-03
10-K 2016-02-24 Annual: 2016-01-03
10-Q 2015-10-30 Quarter: 2015-09-27
10-Q 2015-07-31 Quarter: 2015-06-28
10-Q 2015-05-01 Quarter: 2015-03-29
10-K 2015-02-24 Annual: 2014-12-28
10-Q 2014-10-30 Quarter: 2014-09-28
10-Q 2014-08-01 Quarter: 2014-06-29
10-Q 2014-05-02 Quarter: 2014-03-30
10-K 2014-02-21 Annual: 2013-12-29
10-Q 2013-11-04 Quarter: 2013-09-29
10-Q 2013-08-01 Quarter: 2013-06-30
10-Q 2013-05-03 Quarter: 2013-03-31
10-K 2013-02-22 Annual: 2012-12-30
10-Q 2012-11-09 Quarter: 2012-09-30
10-Q 2012-08-02 Quarter: 2012-07-01
10-Q 2012-05-07 Quarter: 2012-04-01
10-K 2012-02-23 Annual: 2012-01-01
10-Q 2011-11-08 Quarter: 2011-10-02
10-Q 2011-08-09 Quarter: 2011-07-03
10-Q 2011-05-10 Quarter: 2011-04-03
10-K 2011-02-25 Annual: 2011-01-02
10-Q 2010-11-10 Quarter: 2010-10-03
10-Q 2010-08-11 Quarter: 2010-07-04
10-Q 2010-05-10 Quarter: 2010-04-04
10-K 2010-03-01 Annual: 2010-01-03
8-K 2020-02-12 Regulation FD
8-K 2020-01-22 Earnings, Exhibits
8-K 2019-12-05 Officers, Exhibits
8-K 2019-10-23
8-K 2019-10-15 Earnings, Exhibits
8-K 2019-10-07 Officers
8-K 2019-08-26 Other Events, Exhibits
8-K 2019-07-16 Earnings, Exhibits
8-K 2019-04-25 Shareholder Vote, Other Events, Exhibits
8-K 2019-04-16 Earnings, Exhibits
8-K 2019-04-01 Other Events, Exhibits
8-K 2019-04-01 Other Events, Exhibits
8-K 2019-03-21 Other Events
8-K 2019-01-22 Earnings, Exhibits
8-K 2019-01-17 Other Events, Exhibits
8-K 2018-12-17 Other Events, Exhibits
8-K 2018-10-23 Other Events, Exhibits
8-K 2018-10-16 Earnings, Other Events, Exhibits
8-K 2018-10-02 Other Events, Exhibits
8-K 2018-07-17 Earnings, Exhibits
8-K 2018-06-22 Officers, Regulation FD, Exhibits
8-K 2018-05-14 Regulation FD
8-K 2018-04-26 Shareholder Vote, Other Events, Exhibits
8-K 2018-04-17 Earnings, Exit Costs, Exhibits
8-K 2018-03-20 Officers, Exhibits
8-K 2018-01-23 Earnings, Exhibits

Johnson & Johnson Financials

JNJ Metrics, Comps, Filings

Annual | Quarterly

Business

Johnson & Johnson and its subsidiaries (the Company) have approximately 135,100 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. Johnson & Johnson is a holding company, which has more than 260 operating companies conducting business in virtually all countries of the world. The Company's primary focus is products related to human health and well-being. Johnson & Johnson was incorporated in the State of New Jersey in 1887.

The Executive Committee of Johnson & Johnson is the principal management group responsible for the strategic operations and allocation of the resources of the Company. This Committee oversees and coordinates the activities of the Company's three business segments: Consumer, Pharmaceutical and Medical Devices. Within the strategic parameters provided by the Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies. Each subsidiary within the business segments is, with limited exceptions, managed by residents of the country where located.

The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. Additional information required by this item is incorporated herein by reference to the narrative and tabular descriptions of segments and operating results under: "Item 7. Management's Discussion and Analysis of Results of Operations and Financial Condition" of this Report; and Note 18 "Segments of Business and Geographic Areas" of the Notes to Consolidated Financial Statements included in Item 8 of this Report.


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Stockholders' Equity

Income Statement ($BB Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($BB Annual)

Operating, Investing, Financing

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Johnson & Johnson (JNJ) 379,441 67% 14.8 11% 155,117 94,332 81,325 54,220 16,332 26,618 392,764
Pfizer (PFE) 249,913 80% 17.8 8% 156,199 96,274 53,657 42,879 12,674 16,080 286,383
Merck (MRK) 217,623 70% 14.1 11% 83,965 56,330 44,368 31,007 9,370 16,585 233,734
GlaxoSmithKline (GSK) 200,316 0% 58,066 54,394 0 0 0 0 225,704
Novartis (NVS) 197,050 0% 145,563 66,871 0 0 0 0 193,929
Abbott (ABT) 149,087 57% 22.9 4% 68,427 36,741 30,935 17,651 2,895 7,217 164,940
Eli Lilly (LLY) 106,241 77% 11.8 20% 38,666 35,809 23,229 17,810 7,843 9,937 117,668
AbbVie (ABBV) 100,912 77% 18.0 7% 57,142 65,708 32,624 25,254 4,118 7,085 127,359
Beigene (BGNE) 98,573 88% -152.1 -31% 2,150 579 434 383 -664 -642 97,723
Bristol Myers Squibb (BMY) 73,829 53% 8.4 11% 55,163 39,012 23,857 12,640 6,226 8,365 69,858
Celgene (CELG) 67,154 96% 10.4 13% 39,183 29,132 16,354 15,736 5,271 7,702 79,730
GW Pharmaceuticals (GWPH) 64,239 88% -1,554.6 -6% 843 114 114 100 -50 -41 63,656
Allergan (AGN) 54,767 85% 80.8 -4% 123,846 38,273 15,678 13,341 -5,356 939 75,841
Zoetis (ZTS) 54,569 67% 25.9 13% 10,986 8,575 6,046 4,046 1,375 2,291 59,314
Sanofi (SNY) 52,845 0% 111,408 0 0 0 0 52,184
Vertex Pharmaceuticals (VRTX) 46,842 87% 16.9 33% 7,033 1,964 3,454 2,990 2,355 2,569 43,540
Regeneron Pharmaceuticals (REGN) 35,984 0% 15.2 16% 13,174 3,418 7,237 0 2,069 2,295 34,925
Alexion Pharmaceuticals (ALXN) 28,246 71% 15.7 9% 14,568 4,404 4,499 3,191 1,334 1,835 28,827
Biomarin Pharmaceutical (BMRN) 15,774 79% 680.7 -3% 4,393 1,432 1,533 1,213 -110 24 16,336
Elanco Animal Health (ELAN) 12,085 52% 30.6 2% 8,857 3,591 3,073 1,591 144 460 14,098

Balance Sheet ($MM)2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash15,81019,35532,26121,08929,20633,08913,73218,97217,82418,107
Accounts Receivable9,6469,77410,58111,30911,71310,98510,73411,69913,49014,098
Inventory5,1805,3786,2857,4957,8788,1848,0538,1448,7658,599
PP&E14,75914,55314,73916,09737,13336,68515,90515,91217,00517,035
Assets94,682102,908113,644121,347132,683131,119133,411141,208157,303152,954
Accounts Payable5,5415,6235,7255,8316,2667,6336,6686,9187,3107,537
Long-Term Debt8,2239,16912,96911,48913,32815,12212,85722,44232,17530,284
Liabilities44,09446,32956,56456,52158,63061,36762,26170,79097,14393,202
Stockholders' Equity
Income Statement ($MM)2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Revenue61,89761,58765,03067,22471,31274,33170,07471,89076,45081,581
Cost of Revenue18,44718,79220,36021,65822,34222,74621,53621,68525,35427,091
Gross Profit43,45042,79544,67045,56648,97051,58548,53850,20551,09654,490
R&D6,9866,8447,5487,6658,1838,4949,0469,09510,55410,775
SG&A19,80119,42420,96920,86921,83021,95421,20319,94521,42022,540
Tax3,4893,6132,6893,2613,1553,5362,8652,84316,3732,702
Net Income12,26613,3349,67210,51413,83116,32315,40916,5401,30015,297
Cash Flow ($MM)2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash Operating16,57116,38514,29815,39617,41418,47119,27918,76721,05622,201
Cash Investing-7,598-7,854-4,612-4,510-5,103-12,305-7,735-4,761-14,868-3,167
Cash Financing-4,092-4,980-4,452-20,562-6,091-12,260-10,846-8,551-7,673-18,510